Divergent U.S. and UK timelines require tailored clinical trial design and funding.
Key takeaways
Private and mid-cap medtech firms are driving more trials and approvals as innovation pathways shift.
Capital constraints and regulatory complexity are reshaping where and how devices are developed.
TREND: Medtech innovation is shifting
As medtech innovation continues to shift, companies will need to be more deliberate in how they invest in, develop and bring new devices to market. Medtech companies should prioritize capital efficiency, portfolio focus and strategic trials rather than simply increasing R&D levels.
TREND: Clinical trial timelines in flux
As clinical trial timelines compress in the U.S. and lengthen in the UK, life sciences companies should proactively tailor trial design, geography and funding strategies to each market’s realities.
Subscribe to Life Sciences Insights
Knowledge is power. Stay up to date with key life sciences trends and timely insights, delivered straight to your inbox.
